Linagliptin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Linagliptin: From Type 2 Diabetes Mellitus to Opsismodysplasia
One-Sentence Summary
Linagliptin is an oral DPP-4 inhibitor originally used to treat type 2 diabetes mellitus. The TxGNN model predicts it may be effective for opsismodysplasia, a rare skeletal dysplasia. Currently there are 0 clinical trials and 0 publications supporting this prediction, so it is a model-only signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 diabetes mellitus |
| Predicted New Indication | Opsismodysplasia |
| TxGNN Prediction Score | 94.90% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 6 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, linagliptin is a DPP-4 inhibitor. It prolongs incretin activity and lowers blood glucose in type 2 diabetes, and this efficacy is well established.
Opsismodysplasia is a skeletal dysplasia caused by loss-of-function variants in INPPL1 (SHIP2). No plausible mechanistic link to DPP-4 inhibition has been identified. The high TxGNN score (94.90%) is a graph-based prediction and is not backed by any trial or literature evidence, so it should be treated as a hypothesis only.
Other top-ranked predictions are also supported by no clinical evidence and have weak or implausible mechanistic rationale. They include thiamine-responsive dysfunction syndrome, classic stiff person syndrome, focal stiff limb syndrome, several localized lipodystrophies, pancreatic agenesis and homozygous familial hypercholesterolemia. For pancreatic agenesis, two papers were retrieved, but they concern linagliptin in type 2 diabetes and DPP-4 inhibitor tolerability, not the predicted disease.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for opsismodysplasia.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN14101P | Trajenta Film-Coated Tablets 5mg | Film-coated tablet | Not specified in the data compiled |
| SIN14377P | Trajenta Duo Film-Coated Tablets 2.5mg / 500mg | Film-coated tablet | Not specified in the data compiled |
| SIN14378P | Trajenta Duo Film-Coated Tablets 2.5mg / 850mg | Film-coated tablet | Not specified in the data compiled |
| SIN14379P | Trajenta Duo Film-Coated Tablets 2.5mg / 1000mg | Film-coated tablet | Not specified in the data compiled |
| SIN15273P | Glyxambi Film-Coated Tablets 10 mg/5 mg | Film-coated tablet | Not specified in the data compiled |
A sixth licence (SIN15272P, Glyxambi 25 mg/5 mg) is also valid. All six registrations are active and none are cancelled.
Safety Considerations
- Contraindication-related conditions (from a knowledge graph, not label text): hypoglycaemia and pancreatitis.
- Drug Interactions: 100 interactions were found. The sample reviewed was mostly Moderate, with a few Minor. Examples of Moderate interactions include:
- sympathomimetics and bronchodilators (phenylephrine, pseudoephedrine, epinephrine, salbutamol, formoterol)
- corticosteroids (hydrocortisone)
- hormonal agents (estradiol, levonorgestrel, norethisterone, desogestrel)
- other drugs (hydrochlorothiazide, benazepril, acetazolamide, alpelisib, apalutamide, amobarbital, ethanol, abametapir topical)
- Minor examples are topical hydrocortisone and topical alclometasone.
For the full warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a graph-based score. There are no clinical trials or literature, and no plausible mechanistic link between DPP-4 inhibition and INPPL1-related skeletal dysplasia. Linagliptin is well established in type 2 diabetes in Singapore, but that does not support the new indication.
To proceed, the following is needed:
- Mechanism of action data and a credible biological rationale linking DPP-4 inhibition to the SHIP2/INPPL1 pathway
- Preclinical or disease-model evidence for opsismodysplasia
- Package insert warnings and contraindications from HSA, to allow safety screening
- A pathophysiology review of the other top-ranked predictions, to see whether any has a stronger rationale
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.